A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
收藏DataCite Commons2026-03-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00002502/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.
提供机构：
Vivli
创建时间：
2018-10-27
